{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:35:06Z","timestamp":1769834106928,"version":"3.49.0"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>EZH2, a subunit of the polycomb repressive complex 2 (PRC2), is an important methyltransferase that catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3). EZH2 is overexpressed in various malignancies. Here, we investigated EZH2 expression and potential signaling molecules that correlate with EZH2 expression in ATLL and other T-cell neoplasms. Immunohistochemical staining (IHC) was performed for EZH2, pERK, MYC, and pSTAT3 on 43 ATLL cases and 104 cases of other T-cell neoplasms. Further IHC studies were conducted for Ki-67, SUZ12, and H3K27me3 on ATLL cases. All ATLL cases showed EZH2 overexpression. In other T-cell neoplasms, a high prevalence of EZH2 overexpression was identified (86%), except for T-PLL (33%). In ATLL, EZH2 overexpression correlated with pERK co-expression (86%), while only a small subset of cases showed MYC (7%) or pSTAT3 (14%) co-expression. In the other T-cell neoplasms, there was a variable, but higher, co-expression of EZH2 with pERK, MYC, and pSTAT3. In ATLL, enhanced EZH2 expression correlated with higher Ki-67 staining, SUZ12 (another PRC2 subunit), and H3K27me3 co-expression. In conclusion, EZH2 is overexpressed in ATLL and is associated with pERK expression. It correlates with an increased proliferation index, indicating an aggressive clinical course. EZH2 also correlates with SUZ12 and H3K27me3 co-expression, suggesting its PRC2-dependent catalytic activity through trimethylation. Additionally, EZH2 is overexpressed in most T-cell neoplasms, suggesting that EZH2 could function as an oncogenic protein in T-cell tumorigenesis. EZH2 and pERK could serve as potential therapeutic targets for treating aggressive ATLL. EZH2 could also be targeted in other T-cell neoplasms.<\/jats:p>","DOI":"10.3390\/cancers16030646","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:42:32Z","timestamp":1706866952000},"page":"646","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia\/Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-8218","authenticated-orcid":false,"given":"Jiani","family":"Chai","sequence":"first","affiliation":[{"name":"Montefiore Medical Center, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-0250","authenticated-orcid":false,"given":"Jui","family":"Choudhuri","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald Z.","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-4300","authenticated-orcid":false,"given":"Xuejun","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb Complex PRC2 and Its Mark in Life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in Cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.18632\/oncotarget.6612","article-title":"Prognostic Value of High EZH2 Expression in Patients with Different Types of Cancer: A Systematic Review with Meta-Analysis","volume":"7","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2017.174","article-title":"Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Histiocytic and Dendritic Cell Neoplasms with Evidence for p-ERK1\/2-Related, but Not MYC- or p-STAT3-Related Cell Signaling","volume":"31","author":"Tian","year":"2018","journal-title":"Modern Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","article-title":"Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Small Cell and Aggressive B-Cell Non-Hodgkin Lymphomas and Differential Regulation of EZH2 Expression by p-ERK1\/2 and MYC in Aggressive B-Cell Lymphomas","volume":"29","author":"Tian","year":"2016","journal-title":"Modern Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/PAS.0000000000001180","article-title":"Utility of Combined EZH2, p-ERK1\/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-Positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas","volume":"43","author":"Tian","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in Normal Hematopoiesis and Hematological Malignancies","volume":"7","author":"Herviou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41379-021-00885-9","article-title":"EZH2 Expression Is Associated with Inferior Overall Survival in Mantle Cell Lymphoma","volume":"34","author":"Sakhdari","year":"2021","journal-title":"Modern Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","article-title":"Enhancer of Zeste Homolog 2 Is Widely Expressed in T-Cell Neoplasms, Is Associated with High Proliferation Rate and Correlates with MYC and PSTAT3 Expression in a Subset of Cases","volume":"56","author":"Shi","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: A Novel Target for Cancer Treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-Dependent Epigenetic Landscape in Adult T-Cell Leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 Is Downstream of the PRB-E2F Pathway, Essential for Proliferation and Amplified in Cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/onc.2011.118","article-title":"MEK\u2013ERK Pathway Regulates EZH2 Overexpression in Association with Aggressive Breast Cancer Subtypes","volume":"30","author":"Fujii","year":"2011","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 Signaling Drives EZH2 Transcriptional Activation and Mediates Poor Prognosis in Gastric Cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.18632\/oncotarget.327","article-title":"Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-Transcriptional Mechanisms","volume":"2","author":"Koh","year":"2011","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","article-title":"Polycomb-Mediated Loss of MiR-31 Activates NIK-Dependent NF-\u039aB Pathway in Adult T Cell Leukemia and Other Cancers","volume":"21","author":"Yamagishi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.2823","article-title":"Activated Oncogenic Pathways and Therapeutic Targets in Extranodal Nasal-type NK\/T Cell Lymphoma Revealed by Gene Expression Profiling","volume":"223","author":"Ng","year":"2011","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 Overexpression in Natural Killer\/T-Cell Lymphoma Confers Growth Advantage Independently of Histone Methyltransferase Activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2021.10.038","article-title":"Abnormal TP53 Predicts Risk of Progression in Patients with Barrett\u2019s Esophagus Regardless of a Diagnosis of Dysplasia","volume":"162","author":"Redston","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 Expression Is Associated with High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast","volume":"24","author":"Bachmann","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective Inhibition of Ezh2 by a Small Molecule Inhibitor Blocks Tumor Cells Proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","article-title":"Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth","volume":"20","author":"Nasveschuk","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel Orally Bioavailable EZH1\/2 Dual Inhibitors with Greater Antitumor Efficacy than an EZH2 Selective Inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective Inhibition of EZH2 and EZH1 Enzymatic Activity by a Small Molecule Suppresses MLL-Rearranged Leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S1470-2045(20)30530-1","article-title":"EZH2 Inhibition for Epithelioid Sarcoma and Follicular Lymphoma","volume":"21","author":"Groisberg","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/bloodadvances.2019001256","article-title":"Targeting EZH2 for the Treatment of Hepatosplenic T-Cell Lymphoma","volume":"4","author":"Pikman","year":"2020","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An Open-Label, Single-Arm Phase 2 Trial of Valemetostat for Relapsed or Refractory Adult T-Cell Leukemia\/Lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and Survival among 1594 Patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/646\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:01Z","timestamp":1760104441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/3\/646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16030646"],"URL":"https:\/\/doi.org\/10.3390\/cancers16030646","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}